09:13 AM EDT, 04/04/2025 (MT Newswires) -- Health care stocks were declining pre-bell Friday, with The Health Care Select Sector SPDR Fund ( XLV ) down 0.5% and the iShares Biotechnology ETF (IBB) 1.6% lower.

Mesoblast (MESO) said it considers its allogeneic cellular therapies, including Ryoncil and Revascor, to be US-origin products that will not be subject to tariffs. Shares of Mesoblast were down more than 7% premarket.

AbbVie ( ABBV ) shares were down 1.2% after the company issued Q1 adjusted earnings guidance below analysts' expectations and lowered its 2025 adjusted EPS outlook.

Amgen ( AMGN ) shares were over 1% higher after the company said the US Food and Drug Administration approved Uplizna as treatment for adults with immunoglobulin G4-related disease, a chronic immune-mediated inflammatory condition that can damage multiple organs.